Categories Sites CureVac’s stock soars on GSK’s $1.56 billion deal for COVID-19 and flu vaccines – MarketWatch Post author By Mike Nova Post date July 3, 2024 CureVac’s stock soars on GSK’s $1.56 billion deal for COVID-19 and flu vaccines MarketWatch GSK Secures mRNA Vaccines For Bird Flu, COVID And Seasonal Flu From Struggling Biotech CureVac Forbes GSK buys COVID, influenza vaccines from retrenching CureVac Reuters.com The post CureVac’s stock soars on GSK’s $1.56 billion deal for COVID-19 and flu vaccines – MarketWatch first appeared on The CoronaVirus Alerts – The News And Times. ← A Combination COVID and Flu Vaccine Is Coming Soon – Scientific American → Post debate polls: Joe Biden losing ground to Donald Trump – The Hill
The World Web TimesThe World Web Times